Culig Zoran, ao.Univ.-Prof. Dr.med.univ.

University / Clinic: Innsbruck Medical University
Institute: Department of Urology
 
Research Area: molecular pathology - prostate cancer

Email: zoran.culig@i-med.ac.at
Web: www.zculig.org


Research Topic:
My research interest is in mechanisms relevant to development and progression of human carcinoma of the prostate. In this context, expression and function of androgen receptor and its partner proteins coactivators has been studied. Androgen receptor is also activated by interleukin-6, a pleiotropic cytokine whose levels are elevated in carcinoma of the prostate. Current research is focused on growth regulation by interleukin-6. We have identified novel functions of suppressors of cytokine signaling in prostate cancer. These proteins have a prominent function in regulation of proliferation and apoptosis. покрывала на кровать


Project:
  Transcriptional integrator p300 in human prostate tumor-initiating cells
details ...

Selected publications:
 
  Pichler R, Fritz J, Heidegger I, Steiner E, Culig Z, Klocker H, Fuchs D
The predictive and prognostic role of serum neopterin and tryptophan breakdown in prostate cancer.
Cancer Sci. 2017 Jan 20. doi: 10.1111/cas.13171. [Epub ahead of print]

  Culig Z, Puhr M
Interleukin-6 and prostate cancer: Current developments and unsolved questions
Mol Cell Endocrinol. 2017 Mar 16. pii: S0303-7207(17)30181-8. doi: 10.1016/j.mce.2017.03.012. [Epub

  Pichler R, Gruenbacher G, Culig Z, Brunner A, Fuchs D, Fritz J, Gander H, Rahm A, Thurnher M
Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer.
Cancer Immunol Immunother. 2016 Dec 22. doi: 10.1007/s00262-016-1945-z. [Epub ahead of print]

  Höfer J, Akbor M, Handle F, Ofer P, Puhr M, Parson W, Culig Z, Klocker H, Heidegger I
Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide.
Oncotarget. 2016 Sep 13;7(37):59781-59794. doi: 10.18632/oncotarget.10926.

  Pichler R, Fritz J, Zavadil C, Schäfer G, Culig Z, Brunner A
Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer.
Oncotarget. 2016 Jun 28;7(26):39916-39930. doi: 10.18632/oncotarget.9537.

  Luef B, Handle F, Kharaishvili G, Hager M, Rainer J, Janetschek G, Hruby S, Englberger C, Bouchal J, Santer F, Culig Z
The AR/NCOA1 axis regulates prostate cancer migration by involvement of PRKD1.
Endocr Relat Cancer. 2016 Jun;23(6):495-508. doi: 10.1530/ERC-16-0160. Epub 2016 Jun 2.

  Handle F, Erb H, Luef B, Höfer J, Dietrich D, Parson W, Kristiansen G, Santer F, Culig Z
SOCS3 Modulates the Response to Enzalutamide and Is Regulated by Androgen Receptor Signaling and CpG Methylation in Prostate Cancer Cells.
Mol Cancer Res. 2016 Jun;14(6):574-85. doi: 10.1158/1541-7786.MCR-15-0495. Epub 2016 Apr 6.

  Santer F, Erb H, Oh S, Handle F, Feiersinger G, Luef B, Bu H, Schäfer G, Ploner C, Egger M, Rane J, Maitland N, Klocker H, Eder I, Culig Z
Mechanistic rationale for Mcl1 inhibition during androgen deprivation therapy
Oncotarget. 2015 Mar 20;6(8):6105-22.

  Heidegger I, Höfer J, Luger M, Pichler R, Klocker H, Horninger W, Steiner E, Jochberger S, Culig Z
Is Eotaxin-1 a serum and urinary biomarker for prostate cancer detection and recurrence?
Prostate. 2015 Dec;75(16):1904-9. doi: 10.1002/pros.23086. Epub 2015 Aug 26.

  Pichler R, Borena W, Schäfer G, Manzl C, Culig Z, List S, Neururer S, Von Laer D, Heidegger I, Klocker H, Horninger W, Steiner H, Brunner A
Low prevalence of HPV detection and genotyping in non-muscle invasive bladder cancer using single-step PCR followed by reverse line blot.
World J Urol. 2015 Dec;33(12):2145-51. doi: 10.1007/s00345-015-1539-y. Epub 2015 Mar 19.

  Höfer J, Kern J, Ofer P, Eder I, Schäfer G, Dietrich D, Kristiansen G, Geley S, Rainer J, Gunsilius E, Klocker H, Culig Z, Puhr M
SOCS2 correlates with malignancy and exerts growth-promoting effects in prostate cancer.
Endocr Relat Cancer. 2014 Jan 30;

  Puhr M, Höfer J, Neuwirt H, Eder I, Kern J, Schäfer G, Geley S, Heidegger I, Klocker H, Culig Z
PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells.
Oncotarget. 2014 Dec 15;5(23):12043-56.

  Erb H, Langlechner R, Moser P, Handle F, Casneuf T, Verstraeten K, Schlick B, Schäfer G, Hall B, Sasser K, Culig Z, Santer F
IL-6 sensitizes prostate cancer to the antiproliferative effect of IFNα2 through IRF9.
Endocr Relat Cancer. 2013 Aug 2.

  Höfer J, Schäfer G, Klocker H, Erb H, Mills I, Hengst L, Puhr M, Culig Z
PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21.
Am J Pathol. 2012 May;180(5):2097-107. Epub 2012 Mar 23.

  Puhr M, Höfer J, Schäfer G, Erb H, Oh S, Klocker H, Heidegger I, Neuwirt H, Culig Z
Epithelial to Mesenchymal Transition Leads to Docetaxel Resistance in Prostate Cancer and is Mediated by Reduced Expression of miR-200c and miR-205.
Am J Pathol. 2012 Oct 3. pii: S0002-9440(12)00653-0. doi: 10.1016/j.ajpath.2012.08.011

  Oh S, Erb H, Hobisch A, Santer F, Culig Z
Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways.
Endocr Relat Cancer. 2012 May 3;19(3):305-19.

  Shariat S, Chromecki T, Höfer J, Barbieri C, Scherr D, Karakiewicz P, Roehrborn C, Montorsi F, Culig Z, Cavarretta I
Soluble gp130 Regulates Prostate Cancer Invasion and Progression in an Interleukin-6 Dependent and Independent Manner.
J Urol. 2011 Nov;186(5):2107-14.

  Santer F, Höschele P, Oh S, Erb H, Bouchal J, Cavarretta I, Parson W, Meyers D, Cole P, Culig Z
Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines.
Mol Cancer Ther. 2011 Sep;10(9):1644-55.

  Puhr M, Santer F, Neuwirt H, Marcias G, Hobisch A, Culig Z
SOCS-3 antagonises the proliferative and migratory effects of fibroblast growth factor-2 in prostate cancer by inhibition of p44/p42 MAPK signalling.
Endocr Relat Cancer. 2010 May 18;17(2):525-38. Print 2010 Jun.

  Santer F, Malinowska K, Culig Z, Cavarretta I
Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells
Endocr Relat Cancer 17:241-253, 2010.

  Malinowska K, Neuwirt H, Cavarretta I, Bektic J, Steiner H, Dietrich H, Moser P, Fuchs D, Hobisch A, Culig Z
Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor
Endocr Relat Cancer. 2009 Mar;16(1):155-69. Epub 2008 Nov 14.

  Neuwirt H, Puhr M, Cavarretta I, Mitterberger M, Hobisch A, Culig Z
[Androgens stimulate the expression of SOCS-3 and inhibits their effect on proliferation and secretion]
Aktuelle Urol. 2009 Aug;40(4):231-4. Epub 2009 Jul 24. German.

  Puhr M, Santer F, Neuwirt H, Susani M, Nemeth J, Hobisch A, Kenner L, Culig Z
Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways.
Cancer Res. 2009 Sep 15;69(18):7375-84. Epub 2009 Sep 8.

  Neuwirt H, Puhr M, Santer F, Susani M, Doppler W, Marcias G, Rauch V, Brugger M, Hobisch A, Kenner L, Culig Z
Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases.
Am J Pathol. 2009 May;174(5):1921-30. Epub 2009 Mar 26.

  Neuwirt H, Arias M, Puhr M, Hobisch A, Culig Z
Oligomeric proanthocyanidin complexes (OPC) exert anti-proliferative and pro-apoptotic effects on prostate cancer cells.
Prostate 2008 Nov 1;68(15):1647-54.

  Wegiel B, Bjartell A, Culig Z, Persson JL
Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival
Int J Cancer 122:1521-1529, 2008.

  Neuwirt H, Puhr M, Cavarretta I, Mitterberger M, Hobisch A, Culig Z
Suppressor of cytokine signalling-3 is up-regulated by androgen in prostate cancer cell lines and inhibits androgen-mediated proliferation and secretion.
Endocr Relat Cancer. 2007 Dec;14(4):1007-19

  Heemers HV, Sebo TJ, Debes JD, Regan KM, Raclaw KA, Murphy LM, Hobisch A, Culig Z, Tindall DJ
Androgen deprivation increases p300 expression in prostate cancer cells
Cancer Res 67:3422-3430, 2007.

  Cavarretta I, Neuwirt H, Untergasser G, Moser P, Zaki M, Steiner H, Rumpold H, Fuchs D, Hobisch A, Nemeth J, Culig Z
The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1
Oncogene 26:2822-2832. 2007.

  Bellezza I, Neuwirt H, Nemes C, Cavarretta I, Puhr M, Steiner H, Minelli A, Bartsch G, Offner F, Hobisch A, Doppler W, Culig Z
Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer.
Am J Pathol. 2006 Dec;169(6):2199-208.

  Bellezza I, Neuwirt H, Nemes C, Cavarretta I, Steiner H, Minelli A, Bartsch G, Offner F, Hobisch A, Doppler W, Culig Z
“Suppressor of cytokine signalling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer”
Am J Patho 2006 Dec;169(6):2199-208. *joint first authors

  Cavarretta I, Neuwirt H, Untergasser G, Moser P, Zaki M, Steiner H, Rumpold H, Fuchs D, Hobisch A, Nemeth J, Culig Z
“The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by mcl-1”
Oncogene. 2006 Oct 30; [Epub ahead of print]

  Neuwirt H, Müller H, Cavarretta I, Tiefenthaler M, Bartsch G, Konwalinka G, Culig Z
“Akacid-medical-formulation, a novel biocidal oligoguanidine with antitumor activity reduces S-phase in prostate cancer cell lines through the Erk 1/2 mitogen-activated protein kinase pathway.“
Int J Onc. 2006 Aug;29(2):503-12.

  Godoy-Tundidor S, Cavarretta I, Fuchs D, Fiechtl M, Steiner H, Friedbichler K, Bartsch G, Hobisch A, Culig Z
Interleukin-6 and oncostatin M stimulation of proliferation of prostate cancer 22Rv1 cells through the signaling pathways of p38 mitogen-activated kinase and phosphatidylinositol 3-kinase
Prostate 64:209-216, 2005.

  Debes J, Comuzzi B, Schmidt L, Dehm S, Culig Z, Tindall D
p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6
Cancer Res 65:5965-5973, 2005.

  Comuzzi B, Nemes C, Schmidt S, Jasarevic Z, Lodde M, Pycha A, Bartsch G, Offner F, Culig Z, Hobisch A
The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer
J Pathol 204:159-166, 2004.

  Comuzzi B, Lambrinidis L, Rogatsch H, Godoy-Tundidor S, Knezevic N, Krhen I, Marekovic Z, Bartsch G, Klocker H, Hobisch A, Culig Z
The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function
Am J Pathol 162:233-241, 2003.

  Steiner H, Godoy-Tundidor S, Rogatsch H, Berger A, Fuchs D, Comuzzi B, Bartsch G, Hobisch A, Culig Z
Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway
Am J Pathol 162:655-663, 2003